Cargando…
KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
KRAS is the most frequently mutated oncogene in non‐small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and...
Autores principales: | Nagy, Ádám, Pongor, Lőrinc Sándor, Szabó, András, Santarpia, Mariacarmela, Győrffy, Balázs |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299512/ https://www.ncbi.nlm.nih.gov/pubmed/27859136 http://dx.doi.org/10.1002/ijc.30509 |
Ejemplares similares
-
Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
por: Eilertsen, Ina A., et al.
Publicado: (2018) -
Gene signature of circulating platelet‐bound neutrophils is associated with poor prognosis in cancer patients
por: Lecot, Pacôme, et al.
Publicado: (2022) -
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma
por: Alshalalfa, Mohammed, et al.
Publicado: (2019) -
Ovarian cancer‐derived copy number alterations signatures are prognostic in chemoradiotherapy‐treated head and neck squamous cell carcinoma
por: Essers, Paul B.M., et al.
Publicado: (2020) -
Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)